치매 환자에서 뇌 자기공명영상의 특징과 비정형 항정신병 약제 사용여부의 상관 관계 = Association between Characteristics of Brain Magnetic Resonance Imaging and Atypical Antipsychotics Use in Dementia Patients

다국어 초록 (Multilingual Abstract)

Objectives We aimed to identify the neuroimaging marker for prediction of the use of atypical antipsychotics (AAP) in dementia patients. Methods From April 2010 to March 2013, 31 patients who were diagnosed as dementia at the psychiatric department of Soonchunhyang University Hospital, completed the brain magnetic resonance imaging scan and cognitive test for dementia. Ten patients were treated with AAP for the improvement of behavioral and psychological symptoms of dementia (BPSD) and the other 21patients were not. Using T1 weighted and Fluid Attenuated Inversion Recovery (FLAIR) images of brain, areas of white matter (WM), gray matter (GM), cerebrospinal fluid (CSF) and white matter hyperintensities (WMH) have been segmented and measured. Multivariate logistic regression models were applied for assessment of association between AAP use and the GM/WM ratio, the WMH/whole brain (GM + WM + CSF) ratio. Results There was a significant association between AAP use and the GM/WM ratio (odds ratio, OR = 1.18, 95% confidence interval, CI 1.01-1.38, p = 0.037), while there was no association between AAP use and the WMH/whole brain ratio (OR = 0.82, 95% CI 0.27-2.48, p = 0.73). Conclusions The GM/WM ratio could be a biological marker for the prediction of AAP use and BPSD in patients with dementia. It was more likely to increase as dementia progress since atrophy of WM was more prominent than that of GM over aging.

참고문헌 (Reference)

1 Salat DH, "White matter pathology isolates the hippocampal formation in Alzheimer’s disease" 31 : 244-256, 2010

2 Guttmann CR, "White matter changes with normal aging" 50 : 972-978, 1998

3 Ashburner J, "Voxel-based morphometry--the methods" 11 (11): 805-821, 2000

4 Staff RT, "Venneri A. Delusions in Alzheimer’s disease: spet evidence of right hemispheric dysfunction" 35 : 549-560, 1999

5 Ballard C, "The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease" CD003476-, 2006

6 Beeri MS, "The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer’s disease patients" 17 : 403-408, 2002

7 O’Dwyer L, "Tanner C, et al. Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer’s disease" 6 : e21745-, 2011

8 Villain N, "Sequential relationships between grey matter and white matter atrophy and brain metabolic abnormalities in early Alzheimer’s disease" 133 : 3301-3314, 2010

9 Li S, "Regional white matter decreases in Alzheimer’s disease using optimized voxel-based morphometry" 49 : 84-90, 2008

10 "Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances"

11 Krishnan KR, "Provenzale JM, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression" 55 : 390-397, 2004

12 CalvÓ-Perxas L, "Profile and variables related to antipsychotic consumption according to dementia subtypes" 24 : 940-947, 2012

13 Assal F, "Neuropsychiatric symptoms in the dementias" 15 : 445-450, 2002

14 Shin IS, "Neuropsychiatric symptoms and quality of life in Alzheimer disease" 13 : 469-474, 2005

15 Berlow YA, "Neuropsychiatric correlates of white matter hyperintensities in Alzheimer’s disease" 25 : 780-788, 2010

16 Englund E, "Neuropathology of white matter changes in Alzheimer’s disease and vascular dementia" 9 (9): 6-12, 1998

17 Bruen PD, "Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease" 131 (131): 2455-2463, 2008

18 Rosen HJ, "Neuroanatomical correlates of behavioural disorders in dementia" 128 (128): 2612-2625, 2005

19 Bosch B, "Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance" 33 : 61-74, 2012

20 Brickman AM, "Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease" 65 : 1202-1208, 2008

21 Dempster AP, "Maximum Likelihood from Incomplete Data via the EM Algorithm" 39 : 1-38, 1977

22 Berger G, "Longitudinal study on the relationship between symptomatology of dementia and levels of subjective burden and depression among family caregivers in memory clinic patients" 18 : 119-128, 2005

23 Chui HC, "Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease" 51 : 676-681, 1994

24 Choi SH, "Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale" 19 : 585-591, 2001

25 Alves GS, "Different patterns of white matter degeneration using multiple diffusion indices and volumetric data in mild cognitive impairment and Alzheimer patients" 7 : e52859-, 2012

26 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders: text revision" American Psychiatric Association 2000

27 SjÖbeck M, "Decreasing myelin density reflected increasing white matter pathology in Alzheimer’s disease--a neuropathological study" 20 : 919-926, 2005

28 Stricker NH, "Decreased white matter integrity in late myelinating fiber pathways in Alzheimer’s disease supports retrogenesis" 45 : 10-16, 2009

29 Esiri MM, "Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease" 354 : 919-920, 1999

30 Craig AH, "Cerebral blood flow correlates of apathy in Alzheimer disease" 53 : 1116-1120, 1996

31 Fernández M, "COOPERA Study Group. Be havioural symptoms in patients with Alzheimer’s disease and their association with cognitive impairment" 10 : 87-, 2010

32 Benoit M, "Brain perfusion in Alzheimer’s disease with and without apathy: a SPECT study with statistical parametric mapping analysis" 114 : 103-111, 2002

33 Piccininni M, "Behavioral and psychological symptoms in Alzheimer’s disease: frequency and relationship with duration and severity of the disease" 19 : 276-281, 2005

34 Gibson E, "Automatic segmentation of white matter hyperintensities in the elderly using FLAIR images at 3T" 31 : 1311-1322, 2010

35 Ott BR, "Apathy and loss of insight in Alzheimer’s disease: a SPECT imaging study" 8 : 41-46, 1996

36 Liperoti R, "Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD)" 6 : 117-124, 2008

37 Ge Y, "Agerelated total gray matter and white matter changes in normal adult brain. Part I: volumetric MR imaging analysis" 23 : 1327-1333, 2002

38 Bartzokis G, "Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease" 25 : 5-18, 2004

39 Acosta-Cabronero J, "Absolute diffusivities define the landscape of white matter degeneration in Alzheimer’s disease" 133 (133): 529-539, 2010

40 Bai F, "Abnormal integrity of association fiber tracts in amnestic mild cognitive impairment" 278 : 102-106, 2009

41 Luders E, "A voxel-based approach to gray matter asymmetries" 22 : 656-664, 2004

42 Kang Y, "A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients" 15 : 300-308, 1997

43 Sled JG, "A nonparametric method for automatic correction of intensity nonuniformity in MRI data" 17 : 87-97, 1998